CELLULAR immunotherapy shows early clinical remission and favorable safety in treatment-refractory autoimmune disease cohorts. Groundbreaking clinical data presented at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, demonstrate that targeted chimeric antigen receptor approaches induce profound serologic clearing and symptom relief.
Patients presenting with treatment-refractory rheumatoid arthritis often exhaust biologic and targeted disease-modifying agents without achieving clinical control. In the open-label Phase 1 portion of the COMPARE trial, investigators evaluated mivocabtagene autoleucel, an autologous CD19-directed cellular product, in six individuals diagnosed with active, autoantibody-positive disease. Following fludarabine and cyclophosphamide lymphodepletion, patients received a single therapeutic infusion.
The trial met its primary safety endpoint, recording grade 1 cytokine release syndrome in four participants and grade 2 events in two participants. Investigators observed no immune effector cell-associated neurotoxicity syndrome. Following the discontinuation of all prior immunosuppressive drugs, every patient demonstrated clinical gains. By week 36, four participants attained DAS28-CRP remission alongside an ACR70 response. Serologic monitoring revealed a 94% reduction in mutated citrullinated vimentin autoantibodies and an 89% decrease in rheumatoid factor IgM, confirming robust immune depletion.
A complementary focus-group investigation analyzed how adults living with active systemic lupus erythematosus evaluate off-the-shelf, induced pluripotent stem cell-derived allogeneic CAR T-cell therapy. Participants managed extensive medication regimens alongside multiple specialty consultations. When evaluating novel cellular interventions, participants identified safety as their primary therapeutic benchmark while ranking speed of initial clinical response lowest.
Patients emphasized that therapeutic benefit must persist for at least two years to justify preconditioning and treatment risks, expressing a strong preference for durable efficacy extending beyond five years. Study participants favored allogeneic cell products over autologous options due to rapid product availability, shortened inpatient stays, and reduced chemotherapy intensity. Clinicians emphasized that successful clinical adoption requires clear upfront financial planning, dedicated disease expertise, and transparent discussions regarding fertility and manageable toxicity risks.
Reference
Albach F et al. CD19 CAR T-Cell Therapy in Highly Treatment-Refractory Rheumatoid Arthritis: Phase 1 Results from the COMPARE Trial. Abstract. ACR Convergence, November 6–11, 2026.
LASZLO on adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
